Recorlev Developer Strongbridge Secures $53 Million in Financing
Strongbridge Biopharma has entered into an agreement for $50 million in credit and $3 million in equity investment with the healthcare-focused firm CRG to meet the demand for Keveyis (dichlorphenamide) and advance the development of its major therapeutic candidate Recorlev (levoketoconazole). Recorlev is an investigational cortisol synthesis inhibitor under development for the…